SCHEMBL30623469

SCHEMBL30623469

C[C@H]1CC2(CCN1C(=O)OC(C)(C)C)CC(O)c1ccc(Cl)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.39
▸ FNTA P49354 3/20 0.38
▸ FNTB P49356 3/20 0.38
▸ STS P08842 1/20 0.38
▸ NR1H2 P55055 3/20 0.37
▸ RXRA P19793 2/20 0.37
▸ NR1H3 Q13133 2/20 0.37
▸ GRM5 P41594 1/20 0.37
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ CCR5 P51681 1/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35
▸ USP30 Q70CQ3 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25357867 0.85 HSD11B1 (0.40) ALDH1A1MEN1KMT2ACCR5HSD11B1
SCHEMBL30623350 0.80 ALDH1A1 (0.38) ALDH1A1STSNR1H2RXRANR1H3
SCHEMBL26016812 0.80 ALDH1A1 (0.38) ALDH1A1STSNR1H2RXRANR1H3
SCHEMBL30623443 0.76 NR1H2 (0.46) NR1H2RXRANR1H3MEN1KMT2A
SCHEMBL30623285 0.76 ACACB (0.34) ALDH1A1STSNR1H2RXRANR1H3
SCHEMBL25360760 0.76 NR1H2 (0.46) NR1H2RXRANR1H3MEN1KMT2A
SCHEMBL30623411 0.75 GRM5 (0.37) ALDH1A1STSNR1H2RXRANR1H3
SCHEMBL18616707 0.74 GRM5 (0.44) ALDH1A1STSNR1H2RXRANR1H3
SCHEMBL31734998 0.73 DRD2 (0.52) MEN1KMT2AMAPT
SCHEMBL31758782 0.73 IDO1 (0.42) MEN1KMT2AKDM1AUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-06-19 — — US disclosed
EP-4476207-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmaceuticals Incorporated (US) 2024-12-18 — — EP disclosed
WO-2023154314-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PNLIP, SAAL1 ALDH1A1 1983/4885FNTA 1677/4885FNTB 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback